ProLung
757 East South Temple
Suite 150
Salt Lake City
Utah
84102-1230
United States
Tel: 801-736-0729
Fax: 801-906-0333
Website: http://prolungdx.com/
Email: info@prolungdx.com
About ProLung
ProLung's mission is to make a difference in time for lung cancer patients. ProLung is a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer. The Company develops, tests, and commercializes solutions which may shorten the time to diagnosis and expand the therapeutic window for lung cancer patients. ProLung's predictive analytics platform for lung cancer risk stratification is approved for sale in the European Economic Area and for investigational use only in the US.YEAR FOUNDED:
2014
LEADERSHIP:
President and CEO: Steven C. Eror
COO: Michael A. Garff
CMO: Jeff O’Driscoll, MD
Chairman of the Board: Todd Morgan
TECHNOLOGY:
Please click here for ProLung's technology.
PIPELINE:
Please click here for ProLung's pipeline.
11 articles about ProLung
-
IONIQ Sciences to Present at LD Micro Invitational XIII
5/30/2023
ProLung, Inc. dba IONIQ Sciences, Inc. announced that Mr. Jared Bauer, CEO, will present in-person at the 13th annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on June 6-8, 2023.
-
IONIQ Sciences to Present at Biotech Showcase
1/5/2023
ProLung, Inc. dba IONIQ Sciences, Inc. announced it is presenting in person at Biotech Showcase™, the investor conference for innovators.
-
IONIQ Sciences to Present at BioFuture
10/24/2022
ProLung, Inc. dba IONIQ Sciences, Inc. today announced it is presenting at BioFuture and also providing an on-demand company presentation.
-
IONIQ Sciences Unveils LUNA3, Next-Generation Early-Stage Cancer Detection Platform
6/23/2022
ProLung, Inc. dba IONIQ Sciences, Inc. unveiled its next-generation platform called LUNA3™ for early-stage cancer detection.
-
ProLung Shareholder Group Urges Shareholders To Ignore The Company's GOLD Consent Revocation Card And Instead Consent To Enlarge And Enhance The Board Using Its WHITE Consent Card
9/12/2018
Steven C. Eror, the Co-Founder and Former President, CEO and member of the Board of Directors (the "Board") of ProLung, Inc., together with a group of stockholders (the "Group") collectively owning approximately 16.3% of the outstanding common stock of ProLung, issued the following statements today on behalf of the Group regarding its consent solicitation to enlarge and enhance the Board.
-
ProLung Shareholder Group Led by Founder and Former CEO Steve Eror Files Preliminary Consent Materials for the Addition of 8 New Directors to the Board
8/8/2018
Cautions the Board Against any Further Board Appointments or Governance Changes During the Pendency of the Consent Solicitation
-
Former Founder-CEO Steven Eror Announces His Intention to Commence a Consent Solicitation at ProLung to Add Eight Directors to the Board
7/27/2018
Delivers Letter to ProLung Requesting the Board to Establish a Record Date for the Consent Solicitation
-
ProLung Names Director Of Marketing And Business Development
5/12/2017
-
ProLung Installs Chief Accounting Officer
5/12/2017
-
ProLung Announces Closing Of Private Placement Transaction With Proceeds Of $8.2 Million
5/12/2017
-
ProLung Announces The Appointment Of Dr. Robin L. Smith To Its Board Of Directors
2/17/2017